I-CYP2C19 Gene Polymorphism yomuntu

I-CYP2C19 ingenye yezidakamizwa ezibalulekile ezihlanganisa ama-enzymes emndenini we-CYP450. Ama-substrates amaningi e-endogenous kanye cishe no-2% wemithi yomtholampilo agaywa yi-CYP2C19, efana ne-metabolism ye-antiplatelet aggregation inhibitors (njenge-clopidogrel), i-proton pump inhibitors (i-omeprazole), ama-anticonvulsants, njll. I-CYP2C19 yofuzo polymorphisms iphinde ibe nomehluko emithini ehlobene nayo. Lezi zinguquko zamaphuzu ze-*2 (rs4244285) kanye ne-*3 (rs4986893) zibangela ukulahleka komsebenzi we-enzyme ofakwe yisakhi sofuzo se-CYP2C19 kanye nobuthakathaka bekhono le-substrate ye-metabolic, futhi kwandise ukugxila kwegazi, ukuze kubangele ukusabela okubi kwezidakamizwa okuhlobene nokugxila kwegazi. * I-17 (rs12248560) ingakhuphula umsebenzi we-enzyme efakwe yisakhi sofuzo se-CYP2C19, ukukhiqizwa kwama-metabolites asebenzayo, futhi ithuthukise ukuvinjelwa kokuhlangana kweplatelet futhi yandise ingozi yokopha. Kubantu abane-metabolism ehamba kancane yezidakamizwa, ukuthatha imithamo evamile isikhathi eside kuzodala ubuthi obukhulu kanye nemiphumela emibi: ikakhulukazi ukulimala kwesibindi, ukulimala kwesistimu ye-hematopoietic, ukulimala kwesistimu yezinzwa ezimaphakathi, njll., okungaholela ekufeni ezimweni ezimbi kakhulu. Ngokomehluko ngamunye kumetabolism ehambisanayo yezidakamizwa, imvamisa ihlukaniswe yaba ama-phenotypes amane, okuyi-ultra-fast metabolism (UM, *17/*17,*1/*17), i-fast metabolism (RM,*1/*1) , intermediate metabolism (IM, *1/*2, *1/*3), slow metabolism (PM, *2/*3/*2, *3/).